What Dilona AQUA Treats: Main Uses and Benefits

Dilona AQUA is generally used when short-term symptomatic assistance is needed for acute and disruptive symptom patterns. The therapeutic domains discussed align with the standardized use of injectable nonsteroidal anti-inflammatory agents. The medication is applied across contexts where significant discomfort or tension may create noticeable physiological strain.

The medication is commonly used across conditions presenting with recurrent or episodic manifestations, including syndromes like renal colic, biliary colic, acute attacks of gout, pronounced menstrual pain (dysmenorrhea), and symptomatic relief for flare-ups of chronic conditions such as rheumatoid arthritis or osteoarthritis. This helps address symptom clusters that become more disruptive during flare-ups.

One key benefit is providing support that helps ease the overall symptom burden during phases of increased distress or discomfort. The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as postoperative pain management or pain following traumatic injuries.

“The support provided helps patients cope more steadily with symptom fluctuations and contributes to improved comfort.”

---

Quick Fact: Relief for Acute Discomfort
Primary Focus: Managing symptoms related to physical discomfort and heightened physiological activity in acute, short-term scenarios.
Benefit: Assists with maintaining functional stability during episodes of heightened distress.

Regulatory References

1. Official Product Information verified by the FDA

Official Eligibility Profile

Dilona AQUA (Diclofenac Injection) is a prescription medicine whose use is strictly governed by authoritative regulatory documents based on patient eligibility, medical history, and specific conditions.

Populations for whom use is Contraindicated

The medicine must not be used in patients with the following confirmed conditions or history, as specified in regulatory labeling:

• Known hypersensitivity or allergy to diclofenac, aspirin, or any other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), or in patients where NSAIDs precipitate asthma, urticaria, or acute rhinitis.
• Active or history of recurrent stomach or intestinal ulcers, bleeding, or perforation.
• Established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.
• Treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
• Severe renal or hepatic failure.
• Women in the third trimester of pregnancy (after 30 weeks' gestation).

Restricted or Conditional Use

Use is not recommended or requires caution and close monitoring in the following groups:

• Elderly patients (due to increased risk of serious adverse effects).
• Patients with mild to moderate renal or hepatic impairment.
• Patients with cardiovascular risk factors (e.g., uncontrolled hypertension, high cholesterol, diabetes, or smoking).
• Children and adolescents (pediatric use is generally not recommended as safety and suitability are not established for the injection formulation).

Interactions with other medicines and products

Concomitant use of Dilona AQUA (diclofenac) with certain other medicines and products is associated with changes in drug levels or increased risks, as documented in official regulatory labeling.

Documented Pharmacological Interactions

Interacting Product Category	Official Regulatory Statement
Anticoagulants/Antiplatelets (e.g., warfarin, aspirin, clopidogrel)	Increases the risk of bleeding and ulcers in the stomach or intestine. Concomitant use with other NSAIDs (e.g., ibuprofen, naproxen) is not recommended due to increased risk of side effects.
Antihypertensives/Diuretics (e.g., ACE inhibitors, ARBs, furosemide, hydrochlorothiazide)	May reduce the blood pressure lowering effect of these medicines. This combination may also increase the risk of worsening kidney function, particularly in elderly or volume-depleted patients.
Specific Agents (e.g., lithium, digoxin, methotrexate, cyclosporine)	May increase the blood levels and toxicity of these co-administered medicines (e.g., lithium, methotrexate, and cyclosporine). The use of methotrexate and cyclosporine may increase the risk of specific organ toxicity.
Antidiabetics (e.g., insulin, sulfonylureas)	May affect the blood sugar level, requiring adjustment and close monitoring of glucose levels.
Mifepristone	Use of diclofenac may reduce the effect of mifepristone. Diclofenac should not be used for 8 to 12 days after mifepristone administration.
SSRIs/SNRIs (e.g., escitalopram)	Increases the risk of gastrointestinal bleeding and ulcers.
Alcohol	Should not be consumed with this medicine as it may increase the chance of side effects, including severe gastrointestinal bleeding.

Inhibition of Eicosanoid Synthesis

The primary mechanism of Dilona AQUA involves the time-dependent inhibition of Cyclooxygenase ( COX) enzymes, particularly the COX-2 isoform. This action blocks the conversion of Arachidonic acid into key lipid mediators, specifically prostaglandins ( PGE2). The inhibition leads to a systemic reduction in the concentration of local inflammatory mediators. This molecular suppression results in the reduction of localized edema and erythema** pathways.

---

Modulation of Pain and Temperature Pathways

The mechanism modulates both peripheral nociceptive signaling and central thermoregulation pathways. The reduction of PGE2 prevents the sensitization of peripheral nociceptors (pain receptors) and resets the hypothalamic thermoregulatory set point during states of fever. Furthermore, non- COX actions on pathways like ATP-sensitive potassium channels contribute to a modulation of nociceptor excitability. Non- COX actions operate concurrently across central and peripheral pathways.

---

Rapid Pathway Saturation

Dilona AQUA is specifically formulated as an aqueous injectable solution. This route facilitates rapid systemic availability and the achievement of high plasma concentrations. This delivery rate drives the speed at which the drug achieves sufficient concentration at the target enzymes to initiate the molecular inhibitory process. This contributes to a faster rate of COX inhibition onset.

How to Use Dilona AQUA: Administration Guidelines

Administration of Dilona AQUA must only be performed by a qualified healthcare professional in a clinical setting; this medicine is not for self-injection.

The medication is for short-term treatment only and should not be given for more than two days.

---

Administration Detail	Instruction Summary
Route of Administration	Deep intramuscular (IM) injection into the upper outer quadrant of the gluteal muscle, or a slow intravenous (IV) bolus/infusion.
Dosing Schedule (Adults)	The standard single dose is 75 mg. A second dose of 75 mg may be given after 6 hours if necessary.
Maximum Daily Dose	The total daily dose, including all forms of the medicine, must not exceed 150 mg.
Special Administration Rules	The injection site should be alternated for subsequent doses. Patients must be well hydrated prior to intravenous administration.
Age-Group Rules	The medicine should only be administered to adults. Use in children and adolescents is not recommended.

---

IV Infusion Preparation (If Applicable)

Before intravenous infusion, the medicine must be diluted with 100 to 500 mL of 0.9% sodium chloride or 5% glucose solution. The infusion solution must be buffered with sodium bicarbonate injectable solution (e.g., 0.5 mL of 8.4% solution) prior to adding the medicine. For IM injection, buffering is not necessary. The lowest effective dose should be used for the shortest duration possible. The patient should alert the healthcare professional immediately if a scheduled dose is missed.

Research Evidence / Overview of Studies for Dilona AQUA

Indication A: Understanding Chronic Fatigue Patterns

Research explored Dilona AQUA as an agent studied for conditions characterized by fluctuating or episodic manifestations. These studies primarily focused on outcomes reflecting daily functioning or activity level, as well as patient-reported outcomes describing perceived discomfort. Research examined symptoms related to systemic strain, and the data indicate patterns related to how symptoms evolved in the observed populations over defined time intervals.

While research describes the short-term changes measured during the study period, the evidence is limited, and findings were mixed, particularly when reviewing studies that explored outcomes over longer follow-up durations. It appears to be an area where data are still emerging. Furthermore, the results apply only to the specific populations studied, and comparative evidence is lacking to fully contextualize these findings. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Indication B: Acute Joint Swelling Episodes

Dilona AQUA was evaluated in studies focusing on episodes where symptoms become more noticeable, often comparing measured changes to baseline or other analgesic options. These studies monitored outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states. Research highlights changes measured during the study period in conditions associated with acute or disruptive episodes.

Research describes patterns observed in the studies related to outcomes capturing phases of heightened symptom activity. The findings describe how patients reported their experience when symptoms became more noticeable. Studies describe short-term changes observed when applied in research contexts involving fluctuating or unstable symptoms.

However, subgroup findings are uncertain, and there is limited information for long-term outcomes in these conditions. Sample sizes were modest in some of the research exploring short-term symptom changes, meaning evidence quality varies across studies. Research is ongoing, and certainty remains low until more comprehensive data become available. Study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. NG219 Evidence review: pharmacological and non-pharmacological interventions for managing gout flares (NICE Guideline)
2. Diclofenac sodium Prescribing Information (Voltaren Injectable - Regulatory Document)

Common questions about Dilona AQUA (FAQ)

Q: What are the most commonly reported side effects of Dilona AQUA?

According to the official product information, the most frequently documented reactions include side effects at the injection site, headache, dizziness, nausea, vomiting, and indigestion (dyspepsia). These are classified as common in regulatory documentation.

Q: What are the main active ingredients described in Dilona AQUA?

The injectable formulation of Dilona AQUA is documented to contain only one active ingredient, which is diclofenac sodium. This substance is the component described as being responsible for the medicine’s primary pharmacological actions.

Q: What common drugs are specifically listed as having major interactions with Dilona AQUA?

Official regulatory documents highlight interactions that are associated with increased health risks. Major documented interactions include a heightened risk of bleeding when used with anticoagulants (medicines that thin the blood) or antiplatelets. Additionally, its use is described as possibly reducing the effectiveness of some blood pressure medicines.

Q: Can Dilona AQUA be used by older adults?

Official documentation indicates that the use of this medicine requires caution and close monitoring for older adults. This is due to a documented heightened risk of serious adverse effects, particularly gastrointestinal complications.

Q: Is Dilona AQUA generally safe to use long-term?

The injectable form is described in regulatory limits as being for short-term treatment only and typically not administered beyond two days, according to official administration guidelines. Regulatory information notes that documented cardiovascular risks may increase with the duration of use.

Q: Is it normal to feel a mild headache when starting Dilona AQUA?

Headache is listed as a common side effect in the official regulatory documentation for this medicine. The possibility of experiencing a headache is noted under the current safety profile.

Q: What does the 'AQUA' part of the name Dilona AQUA refer to?

The term 'AQUA' in the name refers to the medicine's formulation. It is designed as a sterile injectable solution prepared using an aqueous vehicle, meaning it uses water as the primary solvent. This is a key feature of its delivery system.

Q: What kind of research has been done on Dilona AQUA?

Regulatory reviews describe that research has included controlled clinical studies. These studies have examined the medicine’s effects in acute pain, with some studies comparing outcomes to a placebo or to other analgesic options.

Q: Can Dilona AQUA affect blood pressure readings?

The regulatory safety profile reports that changes in blood pressure, specifically increased blood pressure, have been documented as a possible side effect. Regulatory labeling also describes an interaction where the medicine may reduce the effectiveness of certain blood pressure-lowering medications.

Q: Does Dilona AQUA cause fatigue or drowsiness?

The regulatory safety profile occasionally includes reports of effects such as tiredness or drowsiness (sleepiness). Dizziness is also listed as a common effect in the official product information.

Q: Can Dilona AQUA affect blood sugar levels?

Official information indicates that when this medicine is used alongside anti-diabetic medications, it may affect blood sugar levels and requires careful monitoring. Regulatory labeling does not typically describe the isolated effect on blood sugar in patients without diabetes.

Q: Is Dilona AQUA the same kind of medicine as others for this condition?

The medicine is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This is the same broad category of medicine as other common treatments used to address acute pain and inflammation.

Q: How quickly can someone expect Dilona AQUA to start working?

The formulation is specifically designed for rapid systemic availability, which means it reaches high concentrations in the body quickly. This fast delivery rate facilitates the speed at which the drug achieves sufficient concentration at the target enzymes to begin the molecular inhibitory process.

Q: Can Dilona AQUA cause weight changes?

The safety profile includes reports of weight gain which may be associated with the medicine. This effect is often linked to the risk of fluid retention or swelling.

Q: How long does Dilona AQUA stay in the system after the last use?

According to pharmacokinetic data in official documents, the elimination half-life of the active substance in the bloodstream is approximately 1.3 hours. This half-life describes the period required for the body to reduce the substance's concentration by half.

Q: Does Dilona AQUA interact with common over-the-counter pain relievers?

Official information states that this medicine should not be taken with other NSAID pain relievers like ibuprofen or naproxen. However, official authoritative health information suggests that no interaction risk has been noted with paracetamol.

Q: Can Dilona AQUA affect sleep patterns?

The safety profile occasionally includes reports of feeling tired or sleepy. This factor, which is related to the central nervous system effects, may be a consideration in sleep patterns for some individuals.

Q: Are there any specific foods or drinks that should be avoided with Dilona AQUA?

Regulatory documents specifically state that alcohol should not be consumed with this medicine due to an increased risk of severe side effects. No restrictions on specific common foods or non-alcoholic drinks are typically documented in official labeling.

Q: Does Dilona AQUA have a risk of dependence or addiction?

The medicine is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not classified as a narcotic or a controlled substance and therefore is not associated with the regulatory risk of dependence or addiction.

Q: Are there different strengths of Dilona AQUA available?

The standard single dose detailed in regulatory documents for this specific injectable formulation is 75 mg. Other formulations of the active ingredient may be available in different strengths.

Q: Are there any common reasons why Dilona AQUA might be stopped by a healthcare provider?

Official warnings and safety data highlight that a healthcare professional may reconsider use if a patient has serious cardiovascular risk factors. The medicine may also be stopped if a patient experiences unresolved gastrointestinal side effects such as bleeding or ulcers.

Q: What is the maximum duration for which Dilona AQUA has been studied?

Official administration guidelines state the injectable form should not be given for more than two days. The documented risks, particularly cardiovascular, are noted to potentially increase with the duration of use.

Q: Is it possible to have an allergic reaction to Dilona AQUA?

The product information documents the possibility of a hypersensitivity or allergic reaction. This includes the potential for severe skin and breathing reactions, especially in people with a history of sensitivity to NSAIDs or aspirin.

Q: What does the research say about Dilona AQUA versus placebo in trials?

The efficacy of injectable diclofenac has been established in controlled clinical trials where its effects were compared to a placebo (an inactive substance). These studies assessed its effectiveness in managing pain.

Q: Is the effect of Dilona AQUA the same for men and women according to studies?

Regulatory reviews have noted that clinically relevant studies specifically analyzing whether the effects of diclofenac are the same for men and women are lacking.

Q: Does Dilona AQUA interact with birth control pills?

Official information from authoritative health bodies indicates that diclofenac does not affect the efficacy of standard hormonal contraceptives, including the combined pill or progestogen-only pill.

Q: Can Dilona AQUA be taken with vitamins or herbal supplements?

It is documented that the safety profiles of many herbal remedies and supplements when taken with diclofenac are generally not established through formal testing. Therefore, it is documented that insufficient information exists to establish a safety profile for all combinations.

Q: Is there a generic version available for Dilona AQUA?

The active ingredient in Dilona AQUA, diclofenac sodium, is a widely used compound. It is readily available in multiple generic and brand versions around the world.

How to Store and Dispose of Dilona AQUA Injection

Official regulatory guidelines strictly define the conditions necessary to maintain the stability and safety of Dilona AQUA (Diclofenac) Injection.

Storage Requirement	Official Instructions
Temperature and Environment	Store below 30 C in a cool and dry place. Protect the medicine from light, moisture, and excessive heat. Do not freeze.
Safety and Handling	Keep the medicine out of the reach of children and pets. Use the medicine immediately upon opening and discard any unused portion. Store securely in the original, closed container.
Disposal	The unused medicine and container must be disposed of according to local regulations. The preferred method is through a medication take-back program or an approved hazardous waste disposal facility. If a take-back option is unavailable, scratch out all personal information on the label, mix the medicine with an unpalatable substance like dirt, and place it in a sealed bag before disposal with household trash. Do not flush down a sink or toilet.